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Materials and methods: A prospective, randomized, double-blind, controlled study was conducted
on 100 ASA grade I and II patients of either sex, aged 18–60 years, scheduled for elective lower
abdominal and lower limb surgeries, under spinal anesthesia. Patients who developed post-spinal
anesthesia shivering of grade 3 or 4 were included in the study, and randomly allocated to one
of two groups, group D (n= 50), received Dexmedetomidine in a dose of 0.5 lg/kg diluted in
10 ml isotonic saline slowly I.V. (one minute duration), and group N (n= 50), received
Nefopam in a dose of 0.15 mg/kg diluted in 10 ml isotonic saline slowly I.V. (one minute duration)
when shivering was observed. Time taken for control of shivering, response rate, recurrence rate,
hemodynamics, time to ﬁrst request of rescue analgesic, one-patient cost and adverse effects were
recorded.
Results: The time taken for control of shivering was statistically signiﬁcantly shorter in Nefopam
group (group N) compared with dexmedetomidine group (group D). The average time taken for
disappearance of shivering was 2.35 ± 0.67 min in group N compared with group D
(4.63 ± 1.19 min) (p= 0.041). Patients with incomplete response were more in group D (two
patients in group D compared with nil in group N), but not statistically signiﬁcant and recurrence
rate was one patient in group D compared with nil in group N. Time to ﬁrst request to rescue
316 H.S. Mohamedanalgesic was signiﬁcantly prolonged in group N (351.24 ± 19.71 min) compared with group D
(192.63 ± 9.08 min). One-patient cost was signiﬁcantly lesser in group N (about two £/patient)
compared with group D (about 168 £/patient). Adverse effects such as bradycardia, hypotension
and sedation were observed in Dexmedetomidine group, while pain at injection was noted in
Nefopam group.
Conclusion: Nefopam is better as compared to dexmedetomidine for control of intraoperative shiv-
ering under spinal anesthesia due to its rapid onset, higher response rate, no sedation, lesser hemo-
dynamic alterations, lesser requirements of rescue analgesics and lesser costs.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Spinal anesthesia is known to signiﬁcantly impair thermoregu-
lation through inhibiting vasomotor and shivering responses
and through redistributing heat from core body to peripheral
tissues with subsequent rapid hypothermia during anesthesia
[1]. So, shivering, which is deﬁned as an involuntary oscillatory
muscular activity, is considered a physiological response to
core temperature in an attempt to raise the metabolic heat pro-
duction and is associated with cutaneous vasodilatation [2].
However, shivering can double or even triple oxygen consump-
tion and carbon dioxide production, triggers myocardial ische-
mia, causes arterial hypoxemia, increased intraocular and
intracranial pressures, increases wound pain, delayed wound
healing, and interferes with pulse rate, blood pressure and elec-
trocardiogram (E.C.G.) monitoring [3,4].
Prevention of post-anesthetic shivering (PAS) mainly
entails preventing perioperative heat loss by increasing ambi-
ent temperature of operative room, using conventional warm
air blankets and using warmed intravenous (I.V.) ﬂuids [5].
Although the neurotransmitter pathways involved in the
mechanism of PAS are complex and still anonymous, there
are various pharmacological drugs available for the manage-
ment of PAS such as meperidine, clonidine, tramadol and
ketamine. However, every drug has its own adverse effect
and the ideal anti-shivering still not found [6–8].
Dexmedetomidine is a highly selective a2-adrenoceptor
agonist that has been used as a sedative and is known to reduce
shivering threshold [9]. Nefopam is a non-opioid, non-
sedative, centrally acting analgesic which is known as an effec-
tive for the treatment of shivering [10]. This study is designed
to compare the anti-shivering efﬁcacy (primary outcome vari-
able), hemodynamic effects, possible adverse events, time to
ﬁrst rescue analgesic requirements and one-patient cost (sec-
ondary outcome variables) with either of Dexmedetomidine
or Nefopam during spinal anesthesia.2. Methods
This prospective, randomized, double-blind, clinical study was
conducted at Qena university hospital at the time period from
July 2013 to July 2014. The study protocol was approved by
the ethics committee of Qena faculty of medicine, and written
informed consent was obtained from every patient participat-
ing in the study.
This study was registered at ANZCTR with a trial I.D.
ACTRN 12614001124628, and website;
http://www.ANZCTR.org.au/ACTRN12614001124628.A total of one-hundred patients, of either sex, aged 18–
60 years, American Society of Anesthesiologists (ASA) grade
I and II scheduled for elective lower abdominal and lower limb
surgeries under spinal anesthesia were included. Patients with
known hypersensitivity to dexmedetomidine or nefopam, car-
diopulmonary, renal or hepatic disease, convulsive disorders,
glaucoma, senile enlargement of prostate, patients taking tri-
cyclic antidepressants, procedures requiring transfusion of
blood or blood products, obese patients (body mass
index > 30 kg/m2), patients with a contraindication to spinal
anesthesia, e.g., coagulation disorders, local or general infec-
tion, progressive neurological disorders, patients with failed
or partial spinal block or those who do not agree to participate
in the study were not included in the study.
All patients who fulﬁlled the inclusion criteria and devel-
oped post-spinal anesthesia shivering were enrolled.
Randomization method was done according to computer gen-
erated random table. Allocation concealment was done using
closed envelops to randomize the patients into two groups:
Group D (n= 50) where Dexmedetomidine was administered
at a dose of 0.5 lg/kg I.V. (Precedex) and Group N (n= 50)
who received Nefopam in a dose of 0.15 mg/kg I.V.
(Nopain). Each drug was diluted into 10 ml by isotonic sal-
ine and given by slow I.V. (one minute-duration) at the start
of shivering. In order to facilitate blinding, the test solution
was prepared by the ﬁrst anesthesiologist who is not involved
in the study. Neither the recording (second) anesthesiologist
nor the patients were aware of the kind of the drug.
Upon arrival into the operative room, a 20-Gauge venous
cannula was inserted and a preload of 1000 ml. Ringer’s lactate
solution was infused for 1 h before initiation of spinal anesthe-
sia and maintained at 6 ml/kg/h after spinal anesthesia.
Standard monitors were applied and all baseline parameters
such as heart rate (H.R.), non-invasive blood pressure
(NIBP), oxygen saturation (SpO2), electrocardiography
(E.C.G.) and axillary temperature were recorded before the
start of surgery and thereafter at every 15 min for 1 h and
every 30 min for the rest of observation period.
Under complete septic precautions, patients were placed in
the sitting position and anesthetized locally with Lidocaine
2%, 2 ml. At the level of L3-4 interspace using a 25-Gauge
Quinckie spinal needle (Becton, Dicknson, Spain). After con-
ﬁrming clear and free ﬂow of C.S.F., all patients in the two
groups received drug volume of 3 ml containing 15 mg hyper-
baric bupivacaine hydrochloride (Marcaine Spinal heavy
0.5%, AstraZeneca, Istanbul, Turkey). The level of spinal
block was determined by pinprick at the mid-axillary line after
5 min following spinal anesthesia. When a block of T10 level
was achieved, patients were prepared for operation.
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around 24–25 C for all patients participating in the study.
Oxygen was administered to all patients at a rate of 4 L/min
with Hudson facemask and the patients were covered with
drapes. I.V. ﬂuids and anesthetics were administered at room
temperature.
Shivering was graded using a four point scale as per
Wrench et al. [11];
Grade 0: No shivering.
Grade 1: One or more of the following: piloerection,
peripheral vasoconstriction, peripheral cyanosis but without
visible muscle activity.
Grade 2: Visible muscle activity conﬁned to one muscle
group.
Grade 3: Visible muscle activity in more than one muscle
group.
Grade 4: Gross muscle activity involving the whole body.
Patients who developed either grade 3 or 4 shivering were
included in the study.
The attending anesthesiologist recorded the time in minutes
at which shivering started after spinal anesthesia (onset of shiv-
ering), severity of shivering, time to disappearance of shivering
and response rate. Duration of surgery was recorded and dura-
tion of spinal anesthesia was noted by assessing spontaneousFigure 1 The studrecovery of sensory block using the pin-prick method and
observing spontaneous movements of limbs in the post-
operative period. If shivering recurs, patients were treated with
an additional dose of Dexmedetomidine (0.5 lg/kg) or
Nefopam (0.15 mg/kg) in the respective groups by the same
way mentioned previously and recorded. The degree of seda-
tion was evaluated with a four-point scale as per Filos et al.
[12];
1 – awake and alert; 2 – drowsy, responsive to verbal stim-
uli; 3 – drowsy, arousable to physical stimuli; 4 – unarousable.
This monitoring is continued in the post-operative period till
2 h after spinal block.
Adverse effects such as nausea, vomiting, severe bradycar-
dia (<50/min), hypotension (>20% of baseline), pain at
I.V. injection and sedation score were recorded. Time to ﬁrst
rescue analgesic medication (ketolorac I.V. 30 mg) and one-
patient costs for control of PAS were recorded.3. Sample size
Sample size calculation was done using online power/sample
size calculator (http://www.stat.ubc.ca). The means of time
taken for cessation of post-spinal shivering after treatmenty ﬂow diagram.
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Figure 2 Perioperative heart rate changes in both groups.
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primary end point of this study. We hypothesized that detect-
able difference between the means of time taken for cessation
of post-spinal shivering after treatment with either of both
drugs = 180 s. If we estimated a standard deviation (S.D.)
for this prospective power analysis as 20% and an a-value of
0.05, the power of study would be 90%, sample size calculated
to be 44 patients per group. To reduce the possibility of drop-
outs, we enrolled 50 patients per group.
4. Statistical analysis
Statistical analysis was performed using SPSS statistical pack-
age version 20 (SPSS Inc., Chicago, IL). Numerical data were
presented as mean ± S.D. and categorical data as proportions
(%). The unpaired t-test was used for comparison of the means
of all variables between the two groups. P value of <0.05 was
considered statistically signiﬁcant.
5. Results
A total of 100 patients were enrolled in the present study and
were randomized into two groups of 50 each (n= 50) (Fig. 1).
Both groups were comparable with respect to age, gender,
weight, ASA grade, duration and type of surgery, volume of
intravenous ﬂuid administered and duration of spinal anesthe-
sia (Table 1). Also, axillary temperature was comparable in
both groups during the observation period. Heart rate was sig-
niﬁcantly lower in Dexmedetomidine group compared with
Nefopam group during the study period (Fig. 2). However,
there is no evidence of severe bradycardia (H.R. < 50/min)
in any of the studied patients. Mean arterial pressure (MAP)
was signiﬁcantly lower in Dexmedetomidine group compared
with Nefopam group till 60 min after spinal block, but
increased thereafter (Fig. 3).DEX gp NEFO gp
15 min 30 min 45 min 60 min 90 min 120 min
Figure 3 Perioperative MAP changes in the two studied groups.
Table 2 Parameters for post-spinal anesthesia shivering.
Parameter Dexmedetomidine
group (n= 50)
Nefopam
group
(n= 50)
P
value
Onset of shivering 11.7 ± 5.2 12.3 ± 5.8 0.692
Time for cessation of
shivering after medical
treatment (min)
4.63 ± 1.19 2.35 ± 0.67* 0.031
Response rate 48 (96%) 50 (100%) 0.492
Incomplete response 2 (4%) 0 0.168
Recurrence 1 (2%) 0 0.275
Data are presented as mean ± S.D., number and percentage (%).
* Signiﬁcant.
Table 1 Demographic proﬁle of patients of both groups.
Parameter Dexmedetomidine
group (n= 50)
Nefopam
group
(n= 50)
P
value
Age (years) 37.4 ± 9.8 35.7 ± 8.7 0.693
Gender (M/F) 36/14 35/15 0.549
Weight (kg) 71.6 ± 8.6 73.3 ± 9.4 0.427
Height (cm) 173.6 ± 7.3 171.7 ± 6.5 0.329
ASAI/ASAII 35/15 37/13 0.482
Duration of surgery
(min)
87.4 ± 12.73 83.7 ± 9.12 0.427
Duration of spinal
anesthesia (min)
136.2 ± 14.1 132.7 ± 11.6 0.295
Crystalloids infused
(c.c)
1553 ± 527.2 1483 ± 392.7 0.372
Data are presented as mean ± SD, number. n= number of
patients.
M/F = males/females, ASA= American Society of Anesthesiolo-
gists physical status.
There were no statistically signiﬁcant differences between the two
groups with respect to demographic data, patient’s characteristics
related to spinal anesthesia, duration of surgery and sensory block
level.Shivering disappeared in 48 (96%) patients who received
Dexmedetomidine and 50 (100%) patients who received
Nefopam (Table 2). Both drugs were found to be effective in
Table 4 Time to ﬁrst rescue analgesic and one-patient cost in
both groups.
Parameter Dexmedetomidine
group (n= 50)
Nefopam group
(n= 50)
P
value
Time to 1st rescue
analgesic (min)
162.63 ± 9.08 351.24 ± 19.71* 0.004
One-patient cost
(£)
168 2** 0.0004
Data are presented as mean ± SD.
* Signiﬁcant.
** Highly signiﬁcant.
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was observed in two patients (4%) in Dexmedetomidine group
who was given a rescue dose of Dexmedetomidine (Table 2).
There was no statistically signiﬁcant difference regarding
the time for onset of shivering between the two groups.
However, the mean time interval between the administration
of drug after onset of shivering and disappearance of shivering
was signiﬁcantly shorter in the Nefopam group
(2.35 ± 0.67 min) compared with Dexmedetomidine group
(4.63 ± 1.19 min) (p= 0.031) (Table 2).
Adverse effects such as hypotension, bradycardia and seda-
tion were observed in Dexmedetomidine group while pain at
injection was noted in Nefopam group (Table 3).
Time to ﬁrst rescue analgesic was signiﬁcantly prolonged in
Nefopam group (351.24 ± 19.71 min) compared with
Dexmedetomidine group (162.63 ± 9.08 min) and also one-
patient costs for control of PAS were cheaper signiﬁcantly with
Nefopam group (2 £/patient) compared with Dexmedetomidine
group (168 £/patient) (Table 4).
6. Discussion
Since proper control of PAS necessitates a drug which is not
only effective but also with rapid onset, minor adverse effects,
simple and inexpensive, the results of the present study showed
the superiority of Nefopam over Dexmedetomidine for the
management of post-spinal anesthesia shivering, although
both drugs were nearly equally effective in the control of shiv-
ering, as the time taken for control of shivering was statisti-
cally signiﬁcantly lower in Nefopam group (2.35 ± 0.67 min)
compared with Dexmedetomidine group (4.93 ± 0.93 min)
[p= 0.031]. Bilotta et al. [10] ﬁrst reported that nefopam
was superior to tramadol for the prevention of shivering dur-
ing neuraxial anesthesia. Also, Piper et al. [13] reported that
nefopam is better than clonidine for the prevention of
postanesthetic shivering whereas Kim et al. reported that pro-
phylactic administration of nefopam reduces the incidences
and scores of shivering during spinal anesthesia similar to
meperidine [14]. Furthermore, nefopam maintained heart rate
and mean arterial pressure and this is not surprising as nefo-
pam is known to have positive inotropic and chronotropic
effects. While most antishivering drugs reduce both the thresh-
olds of shivering and vasoconstriction, Alfonsi et al. [15]
reported that nefopam signiﬁcantly reduced only the shiveringTable 3 Incidence of adverse effects in both groups.
Parameter Dexmedetomidine
group (n= 50)
Nefopam group
(n= 50)
P
value
Nausea 0 0
Vomiting 0 0
Pain on
injection
0 3 (6%) 0.052
Sedation 12 (24%) 0 0.013
Hypotension 5 (10%) 0 0.041
Bradycardia 7 (14%) 0 0.034
Respiratory
depression
0 0
Tachycardia 0 0
Data are presented as the number of patients (percentage).threshold. Maintaining higher blood pressure may be due to
the nefopam sparing vasoconstriction threshold. Another
advantage of nefopam is that it did not induce sedation at
all. This means that nefopam can be used safely in critically
ill patients with hemodynamic instability because the risks of
sedation and hypotension can be negated.
Nefopam is a non-opioid centrally-acting analgesic. Its
chemical structure is benzoxazocine which is structurally
related to diphenhydramine (an antihistaminic drug) and
orphenadrine (an anti-muscarinic drug). It is used mainly as
an analgesic drug for relief of moderate to severe pain as an
alternative to opioids. It inhibits the synaptosomal uptake of
serotonin, norepinephrine and dopamine, and interacts
directly with a2-adrenoceptors [16], and non-competitive
NMDA antagonist [17]. The additional antishivering effect is
related to the inhibition of monoamine and NMDA receptors.
Contradictory to the present study, Mittal and colleagues
reported that the time taken for cessation of shivering was less
with dexmedetomidine (2.52 ± 0.44 min) when compared to
tramadol in patients scheduled for various surgeries under
spinal anesthesia although both drugs were effective for con-
trol of shivering. Moreover, dexmedetomidine had shown neg-
ligible adverse effects, whereas tramadol is associated with
signiﬁcant nausea and vomiting [18]. The rate of I.V. injection
of dexmedetomidine and the sample size may be the cause of
difference in the time taken for cessation of shivering in both
studies.
The action of dexmedetomidine appears to be due to cen-
tral thermoregulatory inhibition because it comparably
reduces both vasoconstriction and shivering thresholds [19].
The hemodynamic effects of dexmedetomidine are biphasic
as when it is administered I.V., it causes hypotension and
bradycardia until central sympathomimetic effect achieved,
and then it causes moderate decreases in MAP and H.R. [20]
and this explains the drop of B.P. and reduction in H.R.
observed in the dexmedetomidine group compared with the
nefopam group. Sedation more than grade two occurred in
12 patients (24%) in dexmedetomidine group which were in
accordance with the previous studies [9,21]. One contradictory
report was by Karaman et al. according to whom intraopera-
tive dexmedetomidine infusion caused negligible sedation in
spite of using a loading dose of 1 UG/kg followed by a main-
tenance infusion of 0.5 UG/kg/h [22].
Time to ﬁrst rescue analgesic was signiﬁcantly prolonged in
the nefopam group compared with dexmedetomidine group
and this can be attributed to its strong analgesic properties
[16] and this result agreed with other results that proved the
efﬁcacy of nefopam as analgesic [23]. Also, control of PAS
320 H.S. Mohamedwith nefopam was signiﬁcantly cheaper compared with
dexmedetomidine and this is of considerable interest in con-
trolling hospital costs.
Pain at injection is observed in ﬁve patients (10%) in the
nefopam group and it is considered to be related to the way
of administration of nefopam and it resolved spontaneously
in all patients within 5 min.
The limitations of the present study are short duration surg-
eries, as the anti-shivering effect of dexmedetomidine needs to
be observed in surgeries of long duration where hypothermia is
more evident and the core temperature not measured. Also,
some bias may be present as most surgeries performed are
one-day surgery performed under spinal anesthesia which
necessitates rapid recovery of patients. Additionally, we did
not assess different doses of dexmedetomidine.
To conclude, both nefopam and dexmedetomidine are
effective for control of shivering under spinal anesthesia.
However, nefopam is better as compared to dexmedetomidine
due to rapid onset, higher response rate, absence of sedation
and hemodynamic alterations, lesser doses of second rescue
analgesic allover 24 h and lesser one-patient costs. Further
studies to prevent injection pain of nefopam are required.
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